BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BC Innovations | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BC Week In Review | Jan 25, 2019
Clinical News

Verona's ensifentrine misses in Phase II for COPD maintenance

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said both doses of ensifentrine (RPL554) given on top of dual bronchodilator therapy missed the primary endpoint in a Phase II trial as maintenance treatment of chronic obstructive pulmonary disease...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
BC Week In Review | Aug 31, 2018
Company News

Ligand acquiring Vernalis

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) will acquire structured-based drug discovery company Vernalis plc (LSE:VER) for 6.2p per share in cash in a deal the companies say value Vernalis at £32.7 million ($43 million). The price is...
BC Innovations | May 15, 2018
Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Mouse studies suggest nanoparticles loaded with an ADORA2A antagonist and conjugated to CAR T cells could help treat ovarian cancer. The conjugate consists of cross-linked multilamellar liposomal nanoparticles loaded with a tool...
BC Week In Review | Mar 30, 2018
Clinical News

Verona's RPL554 meets in Phase IIb for COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIb trial in 403 patients with moderate to severe chronic obstructive pulmonary disease (COPD) showing that all four doses of RPL554 (VMX554, VRP554) as...
BioCentury | Mar 24, 2018
Product Development

Optimism for A2A

Once considered solely a neurology target, the adenosine pathway has attracted interest in immuno-oncology based on its ability to control whether immune cells adopt a stimulatory or suppressive phenotype. The early results from A2A receptor...
BC Week In Review | Mar 23, 2018
Clinical News

Verona reports Phase IIa data for RPL554 in CF

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in 10 cystic fibrosis patients showing that single doses of 1.5 and 6 mg RPL554 (VMX554, VRP554) both significantly increased mean forced...
BC Week In Review | Dec 15, 2017
Company News

Vernalis, Daiichi in cancer discovery deal

Vernalis plc (LSE:VER) partnered with Daiichi Sankyo Co. Ltd. (Tokyo:4568) to discover compounds against undisclosed cancer targets using Vernalis' fragment and structure-based drug discovery platform. Financial terms are undisclosed. Vernalis plc (LSE:VER), Winnersh, U.K.  Daiichi...
Items per page:
1 - 10 of 651
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BC Innovations | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BC Week In Review | Jan 25, 2019
Clinical News

Verona's ensifentrine misses in Phase II for COPD maintenance

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said both doses of ensifentrine (RPL554) given on top of dual bronchodilator therapy missed the primary endpoint in a Phase II trial as maintenance treatment of chronic obstructive pulmonary disease...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
BC Week In Review | Aug 31, 2018
Company News

Ligand acquiring Vernalis

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) will acquire structured-based drug discovery company Vernalis plc (LSE:VER) for 6.2p per share in cash in a deal the companies say value Vernalis at £32.7 million ($43 million). The price is...
BC Innovations | May 15, 2018
Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Mouse studies suggest nanoparticles loaded with an ADORA2A antagonist and conjugated to CAR T cells could help treat ovarian cancer. The conjugate consists of cross-linked multilamellar liposomal nanoparticles loaded with a tool...
BC Week In Review | Mar 30, 2018
Clinical News

Verona's RPL554 meets in Phase IIb for COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIb trial in 403 patients with moderate to severe chronic obstructive pulmonary disease (COPD) showing that all four doses of RPL554 (VMX554, VRP554) as...
BioCentury | Mar 24, 2018
Product Development

Optimism for A2A

Once considered solely a neurology target, the adenosine pathway has attracted interest in immuno-oncology based on its ability to control whether immune cells adopt a stimulatory or suppressive phenotype. The early results from A2A receptor...
BC Week In Review | Mar 23, 2018
Clinical News

Verona reports Phase IIa data for RPL554 in CF

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in 10 cystic fibrosis patients showing that single doses of 1.5 and 6 mg RPL554 (VMX554, VRP554) both significantly increased mean forced...
BC Week In Review | Dec 15, 2017
Company News

Vernalis, Daiichi in cancer discovery deal

Vernalis plc (LSE:VER) partnered with Daiichi Sankyo Co. Ltd. (Tokyo:4568) to discover compounds against undisclosed cancer targets using Vernalis' fragment and structure-based drug discovery platform. Financial terms are undisclosed. Vernalis plc (LSE:VER), Winnersh, U.K.  Daiichi...
Items per page:
1 - 10 of 651